Testing zamtocabtagene autoleucel in people with B cell lymphoma that came back or did not respond
Original title: DALY II USA/ MB-CART2019.1 for DLBCL
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study in people, so it is still being tested and is not approved care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a treatment called zamtocabtagene autoleucel in people whose B cell lymphoma came back or did not get better with earlier treatment.
Who this trial is for. This study is for people with B cell lymphoma that came back or did not respond to treatment. It includes people with diffuse large B cell lymphoma after at least 2 lines of therapy, people with lymphoma in the brain or spinal cord after at least one line of therapy, people with mantle cell lymphoma or Richter's transformation after at least one line of therapy, and people with diffuse large B cell lymphoma who cannot have a transplant, after at least one line of therapy. Everyone in the study gets the same treatment.
Where it stands. This trial has not reported results. The study team is looking at how well the treatment works, how safe it is, and how the body handles it. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Right now this tells us nothing about whether the treatment helps. It is a study, and the answers are still being collected. If your situation sounds like the people described here, you could ask your care team whether a study like this is worth looking into for you.
What it doesn't mean: This does not mean there is a new treatment you can get from your doctor. A trial is a test, not proven care. Being in a trial does not mean a person will be helped by it. It is not a promise of a cure. Nobody knows yet if this treatment works.
Source: ClinicalTrials.gov, July 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.